Certara, Inc.
NasdaqGS:CERT Stock Report
Certara Past Earnings Performance Certara's earnings have been declining at an average annual rate of -17.2%, while the Healthcare Services industry saw earnings growing at 14% annually. Revenues have been growing at an average rate of 12.4% per year.
Key information
-17.2%
Earnings growth rate
Healthcare Services Industry Growth 1.7% Revenue growth rate 12.4% Return on equity -3.0% Net Margin -8.3% Last Earnings Update 30 Sep 2024
Recent past performance updates
Third quarter 2024 earnings: EPS exceeds analyst expectations Nov 07
Certara, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 10
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 07
Certara, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 04
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 08
Certara, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 10
Show all updates
Price target decreased by 10% to US$14.61 Nov 10
Third quarter 2024 earnings: EPS exceeds analyst expectations Nov 07
Certara, Inc. Updates Earnings Guidance for the Year 2024 Nov 07
Now 21% overvalued Nov 06
Is Certara, Inc. (NASDAQ:CERT) Potentially Undervalued? Oct 24
Certara, Inc. Appoints John Reynders as Independent Board Member Oct 17
Certara, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 10
New minor risk - Profitability Oct 04
Certara, Inc. (NasdaqGS:CERT) completed the acquisition of ChemAxon Kft. Oct 04
Certara (NASDAQ:CERT) Seems To Use Debt Quite Sensibly Sep 20
Certara: Still Awaiting Consistent Growth Sep 16
Now 22% overvalued Sep 13
President & Chief Commercial Officer notifies of intention to sell stock Sep 11
Certara, Inc. (NASDAQ:CERT) Shares Could Be 35% Above Their Intrinsic Value Estimate Aug 31
Certara, Inc. Launches Phoenix™ Version 8.5 Drug Development Software Aug 16
Consensus EPS estimates fall by 317% Aug 13
Price target decreased by 8.8% to US$17.17 Aug 09
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 07
Price target decreased by 9.1% to US$17.72 Aug 07
Certara, Inc. Reiterates Earnings Guidance for the Year 2024 Aug 07
There's Reason For Concern Over Certara, Inc.'s (NASDAQ:CERT) Price Jul 18
Certara, Inc. (NasdaqGS:CERT)signed a definitive agreement to acquire ChemAxon Kft. Jul 10
Certara, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 04
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software Jun 18
Certara (NASDAQ:CERT) Is Looking To Continue Growing Its Returns On Capital Jun 13
Certara, Inc Appoints Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel May 22
Certara, Inc. Reiterates Earnings Guidance for the Year 2024 May 09
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 08
Certara, Inc. Launches Cloud Platform to Further Unify Its End-To-End Scientific Software Platform Apr 16
Certara, Inc., Annual General Meeting, May 21, 2024 Apr 11
When Should You Buy Certara, Inc. (NASDAQ:CERT)? Apr 11
Certara, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 10
Insider notifies of intention to sell stock Apr 04
Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk Mar 21
Consensus EPS estimates increase by 100% Mar 12
Full year 2023 earnings: EPS misses analyst expectations Mar 01
Certara, Inc. Provides Earnings Guidance for the Year 2024 Mar 01
Returns Are Gaining Momentum At Certara (NASDAQ:CERT) Feb 17
Certara, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 02
Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth Jan 30
Price target increased by 8.3% to US$18.57 Jan 24
Certara, Inc. (NasdaqGS : CERT) acquired Applied BioMath, LLC. Dec 14
Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT) Dec 07
Certara, Inc. Announces the Introduction of Simcyp Biopharmaceutics Software Nov 22
Certara, Inc. Provides Revenue Guidance for the Year 2023 Nov 10
Price target decreased by 7.5% to US$17.71 Nov 10
Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT) Oct 31
Price target decreased by 9.7% to US$18.57 Oct 20
Certara, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 12
Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)? Sep 17
President & Chief Commercial Officer notifies of intention to sell stock Sep 13
An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued Aug 30
Consensus EPS estimates fall by 39% Aug 16
Price target decreased by 9.1% to US$21.19 Aug 10
Certara, Inc. Updates Earnings Guidance for the Year 2023 Aug 10
Certara (NASDAQ:CERT) Shareholders Will Want The ROCE Trajectory To Continue Aug 03
Certara, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Jul 14
Insider notifies of intention to sell stock Jun 09
Consensus EPS estimates fall by 20% May 15
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 10
Certara, Inc. Provides Revenue Guidance for the Year 2023 May 09
CEO & Director exercised options and sold US$370k worth of stock Apr 06
Consensus EPS estimates increase by 11% Mar 14
Consensus EPS estimates increase by 15% Mar 10
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 03
Senior VP notifies of intention to sell stock Feb 06
Certara, Inc. to Report Q4, 2022 Results on Mar 01, 2023 Feb 02
Certara, Inc. (NasdaqGS:CERT) acquired VYASA Analytics LLC. Jan 05
Forecast breakeven date pushed back to 2023 Dec 31
Certara, Inc. Announces the Resignation of Mason Slaine as Director of the Company Dec 26 Arsenal Capital Partners completed the acquisition of an additional 18.8% stake in Certara, Inc. (NasdaqGS:CERT) from EQT Avatar Parent L.P.
Certara, Inc. Appoints David Spaight to the Board of Directors Dec 09
President of Software notifies of intention to sell stock Nov 26
Now 22% undervalued after recent price drop Nov 16
Price target decreased to US$20.56 Nov 16
Price target decreased to US$20.56 Nov 13
Third quarter 2022 earnings released: EPS: US$0.025 (vs US$0.012 loss in 3Q 2021) Nov 08 Certara, Inc. Reaffirms Earnings Guidance for the Full Year 2022
Japan's Pharmaceuticals and Medical Devices Agency Renews Licenses of Certara's Software for Evaluating Regulatory Submissions Oct 20
Certara, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 14
Certara: A Story To Watch Sep 27
Insider recently sold US$3.2m worth of stock Aug 18
Now 22% undervalued after recent price drop Aug 17
Certara, Inc. Announces Resignation of Justin Edge as President of Regulatory and Access, Effective September 1, 2022 Aug 13
Certara to raise capital in secondary stock offering Aug 12
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 10
Certara, Inc. Revises Its Full Year Earnings Guidance of 2022 Aug 10
Certara, Inc. Introduces Update of Pinnacle 21(Tm) Enterprise and New Pinnacle 21(Tm) Data Exchange Module Aug 06
Certara, Inc. Appoints Rosemary A. Crane, as a Class III Director, Effective July 21, 2022 Jul 26
Certara, Inc. Appoints Eran Broshy as New Independent Board Member, Effective July 11, 2022 Jul 14
Certara, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 13
Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development Jun 29
Certara, Inc. Announces New Versions of Biosimulation Software for Development of Novel Biologics Jun 22
Revenue & Expenses Breakdown
How Certara makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History NasdaqGS:CERT Revenue, expenses and earnings (USD Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Sep 24 373 -31 119 37 30 Jun 24 364 -79 118 38 31 Mar 24 361 -61 100 37 31 Dec 23 354 -55 94 34 30 Sep 23 353 -34 94 33 30 Jun 23 352 19 98 30 31 Mar 23 344 14 100 30 31 Dec 22 336 15 97 28 30 Sep 22 324 -4 87 28 30 Jun 22 314 -10 95 26 31 Mar 22 301 -12 93 23 31 Dec 21 286 -13 88 20 30 Sep 21 275 -58 134 24 30 Jun 21 262 -55 120 23 31 Mar 21 253 -49 111 21 31 Dec 20 244 -49 106 20 30 Sep 20 233 -1 60 12 30 Jun 20 226 1 58 12 31 Mar 20 215 -5 57 12 31 Dec 19 209 -9 53 12 31 Dec 18 164 -33 51 10
Quality Earnings: CERT is currently unprofitable.
Growing Profit Margin: CERT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CERT is unprofitable, and losses have increased over the past 5 years at a rate of 17.2% per year.
Accelerating Growth: Unable to compare CERT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CERT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (41.4%).
Return on Equity
High ROE: CERT has a negative Return on Equity (-2.95%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
